News
Genetically modified herpes combats advanced cancers
Researchers have found that RP2 – a modified version of the herpes simplex virus – has showed signs of effectiveness in a quarter of patients with a range of advanced cancers.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Researchers have found that RP2 – a modified version of the herpes simplex virus – has showed signs of effectiveness in a quarter of patients with a range of advanced cancers.